| In ZINC since | Heavy atoms | Benign functionality |
|---|---|---|
| November 1st, 2008 | 28 | Yes |
Popular Name: Trifluoperazine dihydrochloride Trifluoperazine dihydrochloride
Find On: PubMed — Wikipedia — Google
CAS Numbers: 117-89-5 , 440-17-5 , 440-17-5, 117-89-5 , 440-17-5, 117-89-5 [trifluoperazine] , 605-75-4 , [117-89-5] , [440-17-5]
10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-10H-phenothiazine
10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-phenothiazine
10-(3-(4-Methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)phenothiazine
10-(gamma-(N'-Methylpiperazino)propyl)-2-trifluoromethylphenothiazine
10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine
10-[3-(4-METHYL-1-PIPERAZINYL)PROPYL]-2-TRIFLUOROMETHYL-PHENOTHIAZINE DIHYDROCHLORIDE
10-[3-(4-METHYL-PIPERAZIN-1-YL)-PROPYL]-2-TRIFLUOROMETHYL-10H-PHENOTHIAZINE
10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine
10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine dihydrochloride
10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine
10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine dihydrochloride
10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine; CPD-7051; trifluoperazine
10H-Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-
10H-Phenothiazine, 10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-
117-89-5; Apo-trifluoperazine (TN); D08636; Trifluoperazine (INN)
117-89-5; C07168; Trifluoperazine
2-Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine
440-17-5; Prestwick_482; Trifluoperazine dihydrochloride
605-75-4; D01448; Trifluoperazine (TN); Trifluoperazine maleate (JAN)
CPD000059133; SAM001247046; TRIFLUOPERAZINE DIHYDROCHLORIDE
CPD000059133; SAM001247046; Tripfluoperazine Hydrochloride
FDA); Trifluoperazine Maleate (JAN)
INN); Trifluoperazine HCl (FDA
INN); Trifluoperazine HCl (JAN
INN); Trifluoperazine Maleate (JAN)
Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-
trifluoperazina; trifluoperazine; trifluoperazinum
Trifluoperazine (dihydrochloride)
Trifluoperazine Hydrochloride (FDA
Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine
Trifluoroperazine Dihydrochloride
Trifluoroperazine Hydrochloride
| Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
|---|---|---|---|---|---|---|---|---|---|---|
| Ref Reference (pH 7) | 5.14 | 11.43 | -38.84 | 1 | 3 | 1 | 13 | 408.513 | 5 | ↓ |
| Hi High (pH 8-9.5) | 5.14 | 9.06 | -5.72 | 0 | 3 | 0 | 11 | 407.505 | 5 | ↓ |
| Mid Mid (pH 6-8) | 5.14 | 11.32 | -44.3 | 1 | 3 | 1 | 13 | 408.513 | 5 | ↓ |
| Note Type | Comments | Provided By |
|---|---|---|
| ALOGPS_SOLUBILITY | 8.76e-03 g/l | DrugBank-approved |
| purity | 9.500000000000000e+001 | Enamine Building Blocks Enamine Building Blocks |
| therap | antipsychotic | MicroSource Spectrum |
| Therapy | Calmodulin antagonist; dopamine receptor antagonist; antipsychotic; sedative | SMDC Iconix |
| UniProt Database Links | CASQ1_RABIT; CDPK1_PLAF7; CDPK1_PLAFK; CDPK1_PLAYO; DSPA_SYNY3; ODB2_ARATH | ChEBI |
| Target | Dopamine Receptor | Selleck Chemicals |
| Patent Database Links | EP1181933; US2007212428 | ChEBI |
| Patent Database Links | EP1547650; EP1627639; EP1754712; EP1808173; EP1815846; EP1815854; EP1829527; EP1829528; EP1829534; EP1844769; EP1923702; EP1990639; US2004132722; US2004142904; US2005009870; US2005014786; US2005080075; US2005080087; US2006166974; US2007203119; US200722537 | ChEBI |
| PUBCHEM_SUBSTANCE_COMMENT | NCC_SAMPLE_SUPPLIER : Tocris Cookson Ltd.; NCC_SUPPLIER_STRUCTURE_ID : 100741; 2 hydrogen chloride | NIH Clinical Collection via PubChem |
| Target | Others | Selleck Chemicals |
| PUBCHEM_SUBSTANCE_COMMENT | SAMPLE_SUPPLIER: Tocris Bioscience; SUPPLIER_STRUCTURE_ID: 100741; SALT: 2 hydrogen chloride | NIH Clinical Collection via PubChem |
| Indications | schizophrenia | KeyOrganics Bioactives |
| Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| 5HT1A-1-E | Serotonin 1a (5-HT1a) Receptor (cluster #1 Of 4), Eukaryotic | Eukaryotes | 411 | 0.32 | Binding ≤ 10μM |
| 5HT2A-1-E | Serotonin 2a (5-HT2a) Receptor (cluster #1 Of 3), Eukaryotic | Eukaryotes | 5 | 0.42 | Binding ≤ 10μM |
| 5HT2B-2-E | Serotonin 2b (5-HT2b) Receptor (cluster #2 Of 4), Eukaryotic | Eukaryotes | 5 | 0.42 | Binding ≤ 10μM |
| 5HT2C-2-E | Serotonin 2c (5-HT2c) Receptor (cluster #2 Of 3), Eukaryotic | Eukaryotes | 5 | 0.42 | Binding ≤ 10μM |
| BGLR-2-E | Beta-glucuronidase (cluster #2 Of 2), Eukaryotic | Eukaryotes | 7800 | 0.26 | Binding ≤ 10μM |
| CALM-2-E | Calmodulin (cluster #2 Of 2), Eukaryotic | Eukaryotes | 1000 | 0.30 | Binding ≤ 10μM |
| EBP-1-E | 3-beta-hydroxysteroid-delta(8),delta(7)-isomerase (cluster #1 Of 1), Eukaryotic | Eukaryotes | 8 | 0.40 | Binding ≤ 10μM |
| LYSC1-1-E | Lysozyme C (cluster #1 Of 2), Eukaryotic | Eukaryotes | 9000 | 0.25 | Binding ≤ 10μM |
| MDR1-2-E | P-glycoprotein 1 (cluster #2 Of 3), Eukaryotic | Eukaryotes | 6500 | 0.26 | Binding ≤ 10μM |
| SCN1A-1-E | Sodium Channel Protein Type I Alpha Subunit (cluster #1 Of 2), Eukaryotic | Eukaryotes | 5000 | 0.27 | Binding ≤ 10μM |
| SCN2A-1-E | Sodium Channel Protein Type II Alpha Subunit (cluster #1 Of 2), Eukaryotic | Eukaryotes | 5000 | 0.27 | Binding ≤ 10μM |
| SCN3A-1-E | Sodium Channel Protein Type III Alpha Subunit (cluster #1 Of 2), Eukaryotic | Eukaryotes | 5000 | 0.27 | Binding ≤ 10μM |
| SCN8A-1-E | Sodium Channel Protein Type VIII Alpha Subunit (cluster #1 Of 2), Eukaryotic | Eukaryotes | 5000 | 0.27 | Binding ≤ 10μM |
| SGMR1-1-E | Sigma Opioid Receptor (cluster #1 Of 6), Eukaryotic | Eukaryotes | 15 | 0.39 | Binding ≤ 10μM |
| DRD2-14-E | Dopamine D2 Receptor (cluster #14 Of 24), Eukaryotic | Eukaryotes | 2 | 0.43 | Binding ≤ 10μM |
| ERG2-2-F | C-8 Sterol Isomerase (cluster #2 Of 2), Fungal | Fungi | 500 | 0.32 | Binding ≤ 10μM |
| PDR5-1-F | Pleiotropic ABC Efflux Transporter Of Multiple Drugs (cluster #1 Of 1), Fungal | Fungi | 1400 | 0.29 | Binding ≤ 10μM |
| Z104304-1-O | Adrenergic Receptor Alpha-1 (cluster #1 Of 3), Other | Other | 350 | 0.32 | Binding ≤ 10μM |
| Z100748-2-O | Neutrophils (cluster #2 Of 2), Other | Other | 6600 | 0.26 | Functional ≤ 10μM |
| Z50380-1-O | Mycobacterium Smegmatis (cluster #1 Of 4), Other | Other | 3150 | 0.28 | Functional ≤ 10μM |
| Z50425-3-O | Plasmodium Falciparum (cluster #3 Of 22), Other | Other | 6000 | 0.26 | Functional ≤ 10μM |
| Z50597-1-O | Rattus Norvegicus (cluster #1 Of 12), Other | Other | 6600 | 0.26 | Functional ≤ 10μM |
| A3EZI9-1-V | Hepatitis C Virus NS3 Protease/helicase (cluster #1 Of 3), Viral | Viruses | 700 | 0.31 | Binding ≤ 10μM |
| Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| EBP_HUMAN | Q15125 | 3-beta-hydroxysteroid-delta(8),delta(7)-isomerase, Human | 8 | 0.40 | Binding ≤ 1μM |
| Z104304 | Z104304 | Adrenergic Receptor Alpha-1 | 29.3 | 0.38 | Binding ≤ 1μM |
| ERG2_YEAST | P32352 | C-8 Sterol Isomerase, Yeast | 500 | 0.32 | Binding ≤ 1μM |
| CALM_HUMAN | P62158 | Calmodulin, Human | 1000 | 0.30 | Binding ≤ 1μM |
| DRD2_RAT | P61169 | Dopamine D2 Receptor, Rat | 0.5322 | 0.46 | Binding ≤ 1μM |
| A3EZI9_9HEPC | A3EZI9 | Hepatitis C Virus NS3 Protease/helicase, 9hepc | 700 | 0.31 | Binding ≤ 1μM |
| 5HT1A_RAT | P19327 | Serotonin 1a (5-HT1a) Receptor, Rat | 411 | 0.32 | Binding ≤ 1μM |
| 5HT2A_RAT | P14842 | Serotonin 2a (5-HT2a) Receptor, Rat | 1.043 | 0.45 | Binding ≤ 1μM |
| 5HT2B_RAT | P30994 | Serotonin 2b (5-HT2b) Receptor, Rat | 1.043 | 0.45 | Binding ≤ 1μM |
| 5HT2C_RAT | P08909 | Serotonin 2c (5-HT2c) Receptor, Rat | 1.043 | 0.45 | Binding ≤ 1μM |
| SGMR1_HUMAN | Q99720 | Sigma Opioid Receptor, Human | 15 | 0.39 | Binding ≤ 1μM |
| EBP_HUMAN | Q15125 | 3-beta-hydroxysteroid-delta(8),delta(7)-isomerase, Human | 8 | 0.40 | Binding ≤ 10μM |
| Z104304 | Z104304 | Adrenergic Receptor Alpha-1 | 29.3 | 0.38 | Binding ≤ 10μM |
| BGLR_RAT | P06760 | Beta-glucuronidase, Rat | 7800 | 0.26 | Binding ≤ 10μM |
| ERG2_YEAST | P32352 | C-8 Sterol Isomerase, Yeast | 500 | 0.32 | Binding ≤ 10μM |
| CALM_HUMAN | P62158 | Calmodulin, Human | 1000 | 0.30 | Binding ≤ 10μM |
| DRD2_RAT | P61169 | Dopamine D2 Receptor, Rat | 0.5322 | 0.46 | Binding ≤ 10μM |
| A3EZI9_9HEPC | A3EZI9 | Hepatitis C Virus NS3 Protease/helicase, 9hepc | 700 | 0.31 | Binding ≤ 10μM |
| LYSC1_RAT | P00697 | Lysozyme C, Rat | 9000 | 0.25 | Binding ≤ 10μM |
| MDR1_HUMAN | P08183 | P-glycoprotein 1, Human | 6500 | 0.26 | Binding ≤ 10μM |
| PDR5_YEAST | P33302 | Pleiotropic ABC Efflux Transporter Of Multiple Drugs, Yeast | 1400 | 0.29 | Binding ≤ 10μM |
| 5HT1A_RAT | P19327 | Serotonin 1a (5-HT1a) Receptor, Rat | 411 | 0.32 | Binding ≤ 10μM |
| 5HT2A_RAT | P14842 | Serotonin 2a (5-HT2a) Receptor, Rat | 1.043 | 0.45 | Binding ≤ 10μM |
| 5HT2B_RAT | P30994 | Serotonin 2b (5-HT2b) Receptor, Rat | 1.043 | 0.45 | Binding ≤ 10μM |
| 5HT2C_RAT | P08909 | Serotonin 2c (5-HT2c) Receptor, Rat | 1.043 | 0.45 | Binding ≤ 10μM |
| SGMR1_HUMAN | Q99720 | Sigma Opioid Receptor, Human | 15 | 0.39 | Binding ≤ 10μM |
| SCN1A_HUMAN | P35498 | Sodium Channel Protein Type I Alpha Subunit, Human | 5000 | 0.27 | Binding ≤ 10μM |
| SCN2A_HUMAN | Q99250 | Sodium Channel Protein Type II Alpha Subunit, Human | 5000 | 0.27 | Binding ≤ 10μM |
| SCN3A_HUMAN | Q9NY46 | Sodium Channel Protein Type III Alpha Subunit, Human | 5000 | 0.27 | Binding ≤ 10μM |
| SCN8A_HUMAN | Q9UQD0 | Sodium Channel Protein Type VIII Alpha Subunit, Human | 5000 | 0.27 | Binding ≤ 10μM |
| Z50380 | Z50380 | Mycobacterium Smegmatis | 3150 | 0.28 | Functional ≤ 10μM |
| Z100748 | Z100748 | Neutrophils | 2700 | 0.28 | Functional ≤ 10μM |
| Z50425 | Z50425 | Plasmodium Falciparum | 3981.07171 | 0.27 | Functional ≤ 10μM |
| Z50597 | Z50597 | Rattus Norvegicus | 2700 | 0.28 | Functional ≤ 10μM |
| Description | Species |
|---|---|
| Abacavir transmembrane transport | |
| ABC-family proteins mediated transport | |
| Activation of Ca-permeable Kainate Receptor | |
| Activation of CaMK IV | |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messenge | |
| Ca2+ pathway | |
| Calmodulin induced events | |
| CaM pathway | |
| Cam-PDE 1 activation | |
| CaMK IV-mediated phosphorylation of CREB | |
| Cholesterol biosynthesis | |
| CREB phosphorylation through the activation of CaMKII | |
| CREB phosphorylation through the activation of CaMKK | |
| DARPP-32 events | |
| Dopamine receptors | |
| eNOS activation | |
| FCERI mediated Ca+2 mobilization | |
| G alpha (i) signalling events | |
| G alpha (q) signalling events | |
| Glycogen breakdown (glycogenolysis) | |
| Inactivation, recovery and regulation of the phototransduction cascade | |
| Interaction between L1 and Ankyrins | |
| Platelet degranulation | |
| Ras activation uopn Ca2+ infux through NMDA receptor | |
| Serotonin receptors | |
| Smooth Muscle Contraction | |
| Synthesis of IP3 and IP4 in the cytosol | |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | |
| Transcriptional activation of mitochondrial biogenesis | |
| Translocation of GLUT4 to the plasma membrane | |
| VEGFR2 mediated cell proliferation | |
| VEGFR2 mediated vascular permeability |